For Health Care Professionals
Get a clear picture of brain amyloid plaques, a pathological hallmark of Alzheimer’s disease.

Our comprehensive portfolio of clinically-validated blood tests combine high precision LC-MS/MS instruments and smart analytics to accurately determine amyloid pathology in the brain.
State-of-the-art proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) methodologies
Blood tests to assess for brain amyloid pathology - The PrecivityAD® and PrecivityAD2® tests
Extensive domain expertise; leading neurological scientists and researchers on staff
PrecivityAD2® and Other Tests
The Precivity® blood tests are tests that health care professionals can order to aid in the diagnosis and treatment of Alzheimer’s disease. The PrecivityAD2® and PrecivityAD® blood tests determine whether a patient with signs or symptoms of memory decline or dementia has high or low likelihood of having changes in the brain that are associated with Alzheimer’s disease. Health care professionals determine which Precivity® test is right for their patient.
PrecivityAD2®
The PrecivityAD2® blood test is intended for use in patients aged 50 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.
Precivity-ApoE®
The Precivity-ApoE® blood test is indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.
Why Diagnose AD
As the number of people living with AD grows, swift, precise diagnosis matters more than ever. An early AD diagnosis can empower patients to proactively manage their health, allow for independent decision-making, and ultimately enhance their quality of life. And while traditional biomarker assessments face barriers and drawbacks, high performing blood tests like PrecivityAD2® can address the need for widely accessible, equitable, and scalable testing options to aid in a timely AD diagnosis.

Advantages of BBM Tests
The PrecivityAD2® test was clinically validated in 583 individuals with cognitive impairment across 2 well-characterized, independent cohorts. The QUIP-II study evaluated how specialists were able to use the PrecivityAD2® test to optimize AD clinical decision-making in 203 patients from real-world settings.
Walter S, Langford O, Jimenez-Maggiora GA, et al. The AlzMatch Pilot Study - Feasibility of remote blood collection of plasma biomarkers for preclinical Alzheimer’s disease trials.J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi.org/10.14283/jpad.2024.101
Angioni D, Hansson O, Bateman RJ, et al. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force. J Prev AlzheimersDis. 2023. doi.org/10.14283/jpad.2023.68
Schindler SE, Li Y, Li M, et al. Using Alzheimer’s disease blood tests to accelerate clinical trial enrollment. Alzheimers Dement. 2023;19(4):1175-1183. doi:10.1002/alz.12754
Health Care Professionals
Order a test
If you are interested in offering the PrecivityAD® test to your patients, please complete the form to start the process for opening a test account and a C₂N representative will be in touch with you shortly.
